Skip to main content

Christopher McNary, Robert Cunningham, Darren Link, Jeffrey Whynall, Jean-Marie Lehn, Sir Aaron Klug, Richard Roberts, Sir Gregory Winter, Francis Collins, Ward Wolff, TLV Kumar

Christopher McNary has been appointed as CEO of RainDance Technologies, the company said last week. He joins RainDance from Thermo Fisher Scientific, where he was vice president and general manager. In the past, he was president and CEO of early-stage start-up companies and held executive management positions at Chiron Diagnostics and Tecan.
Existing RainDance management includes Robert Cunningham, vice president of business development; Darren Link, senior vice president of research and development; and Jeffrey Whynall, vice president of engineering.
Prior to joining RDT, Cunningham co-founded EndoVia Medical to develop a new generation of robotic instruments for minimally invasive surgery. He holds a BA in biology from the University of California, San Diego.
Link, before joining RDT, was a postdoc at Harvard University studying soft materials physics in the department of physics and division of engineering and applied sciences. He holds a BSci in physics from Montana State University and a PhD in physics from the University of Colorado.
Prior to coming to RDT, Whynall was vice president and general manager of Bacou-Dalloz, a company he helped found in 1985. He holds a BS in mechanical engineering from the University of New Hampshire and an MS in electrical engineering from Rensselaer Polytechnic Institute.
RainDance’s scientific advisory board includes Jean-Marie Lehn, a 1987 Nobel Prize winner in chemistry; Sir Aaron Klug, a 1982 Nobel Laureate in chemistry; Richard Roberts, research director at New England Biolabs and a 1993 Nobel Laureate in physiology or medicine; and Sir Gregory Winter, joint head of the division of protein and nucleic acids chemistry of the MRC Laboratory of Molecular Biology in the UK.

The Will Rogers Institute plans to give its annual prize for Outstanding Contributions to Lung Research to Francis Collins, director of the National Human Genome Research Institute, on Dec. 6. The institute said it selected Collins for his research that led to the identification of the CFTR gene that is linked to lung diseases.

Ward Wolff has become executive vice president and chief financial officer of Sangamo BioSciences, the company said this week. In conjunction with his appointment, he resigned from Sangamo’s board of directors. Wolff joins Sangamo from Nuvelo, where he was senior vice president for finance and CFO until the company was restructured in August. In the past, he was senior vice president and CFO of DoubleTwist. Wolff holds an MBA from Harvard Business School and a BA in economics from the University of California, Berkeley.

TLV Kumar has become president of Kinetic Concepts’ Europe, Middle East, and Africa operations. He will report to president and CEO Catherine Burzik, and will be based in the company’s office in Amstelveen, the Netherlands. Kumar used to be president of the Asia-Pacific region at Applied Biosystems.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.